Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
For most women on GLP-1 medications, the realistic goal is lean mass preservation rather than hypertrophy
10.1016/j.ctarc.2020.100242 100 GrunwaldT.BockischB.SpillnerE.RingJ.BredehorstR.OllertM
Reduction in major cardiovascular events (SELECT trial, semaglutide) Reduced risk of progressing from prediabetes to type 2 diabetes (Tirzepatide, 3yr trial) Weight reduction significantly improves sleep apnea severity confirmed in multiple GLP-1 trials Emerging ADA 2026 data on GLP-1 anti-inflammatory effects and osteoarthritis improvement Improved basal metabolic rate and energy utilisation, especially with tirzepatides GIP pathway We believe cost transparency is part of quality care
[1] According to NICE guidance (TA875), Wegovy is recommended for use within specialist weight management services with multidisciplinary support
On The Increase in Use of GLP-1s
US$ 26.09
US$ 27.08
US$ 25.04
US$ 21.45
US$ 24.48
US$ 22.16
US$ 21.89
